GlaxoSmithKline welcomes decision by GAVI Alliance to support introduction of new vaccines against rotavirus and pneumococcal disease

Issued — Wednesday 29th November 2006, Rixensart, Belgium -Following the announcement by the GAVI Alliance today to commit funds to purchase new vaccines against rotavirus and pneumococcal diseases, Jean Stephenne, President and General Manager of GSK Biologicals, said:

“GAVI’s decision today to support the introduction of new vaccines against pneumococcal and rotavirus diseases is another advance for global health. It is our hope that GAVI’s funding plans will ensure that these new products reach those in greatest need and give children the same healthy start regardless of where they live.

GSK Biologicals welcomes this decision as proof that the global health community can work effectively together. With the addition of these new vaccines to its program, GAVI is demonstrating real leadership in helping to ensure children in the poorest countries have access to the best life-saving technologies available now. Rotavirus and pneumococcal disease are some of the biggest threats to children in the developing world, and these new vaccines will help save millions of lives.

We are proud that scientists at GSK Biologicals have devoted years to develop effective vaccines against these killers: our vaccine for rotavirus is now registered in more than 75 countries worldwide and our vaccine candidate for pneumococcal disease is now in late stage clinical development.

GSK is the largest supplier to GAVI and devotes one-third of its vaccine pipeline to diseases that predominantly affect the developing world. We are pleased to partner with GAVI to make these new vaccines available at affordable prices. The GAVI eligible countries will benefit from our tiered pricing model which has been used for more than twenty years to ensure vaccines reach all those who need them.”

About GlaxoSmithKline and GlaxoSmithKline Biologicals

GSK Biologicals (GSK Bio), one of the world’s leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline’s activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. GSK Bio is also developing innovative immunotherapy compounds to treat cancer patients.

In 2005, GSK Bio distributed more than 1.2 billion doses of vaccines to 165 countries in both the developed and the developing world, an average of more than 3 million doses per day.

GlaxoSmithKline — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information please visit www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this [Announcement], are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group’s operations are described under ’Risk Factors’ in the Operating and Financial Review and Prospects in the company’s Annual Report on Form 20-F for 2004.

Contact Information

Nancy Pekarek

US Media enquiries

GlaxoSmithKline

Contact via E-mail